Traditionally hyperdopaminergic state in the basal forebrain has been described as the major pathophysiological basis while subsequent research focussed on the serotonergic system.

Glutamatergic, GABAergic and cholinergic systems are also being targeted. This symposium focuses on recent drug molecules that have been explored like “Asenapine, Iloperidone and Cariprazine” to target this devastating mental disorder in the light of recent advances in the field. The pertinent question is that these above said novel agents promise a lot and deliver a little. Why so? However, the probability of success of a CNS drug to enter the market after successfully passing through all phases of drug development is lower than drugs in other fields of medical research like infectious diseases and diabetes. This has led the clinicians to continue using antipsychotics like olanzapine, risperidone or Amisulpride with limitations of metabolic syndrome or hyperprolactemia. This spate of failures among the new molecules for schizophrenia has led to losing interest by the pharmaceuticals in CNS drug discovery. Thus, in the third part, we wish to discuss the major barriers to developing new successful antipsychotics and suggest possible mitigation strategies. Speakers: Journey of psychiatrist in drug mx of schizophrenia over the last decade: An Overview by Dr Susanta Kumar Padhy Molecules of the Decade- Clinical and pharmacological USP of each of new molecule: A reviewby Dr Jigyansa Ipsita Pattnaik Where we stand today? Evidence versus Experience and what are the ways forward: A view pointby Dr Jayaprakash Russell Ravan Time: 45 minutes Discussion: 10 min